- Home
- BFRI vs NLSP Comparison
BFRI vs NLSP Comparison
Compare BFRI & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRI
- NLSP
- Stock Information
- Founded
- BFRI 1997
- NLSP 2015
- Country
- BFRI United States
- NLSP Switzerland
- Employees
- BFRI N/A
- NLSP N/A
- Industry
- BFRI Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- BFRI Health Care
- NLSP Health Care
- Exchange
- BFRI Nasdaq
- NLSP Nasdaq
- Market Cap
- BFRI 6.2M
- NLSP 6.2M
- IPO Year
- BFRI 2021
- NLSP 2021
- Fundamental
- Price
- BFRI $1.12
- NLSP $2.32
- Analyst Decision
- BFRI Strong Buy
- NLSP
- Analyst Count
- BFRI 1
- NLSP 0
- Target Price
- BFRI $7.00
- NLSP N/A
- AVG Volume (30 Days)
- BFRI 1.3M
- NLSP 2.3M
- Earning Date
- BFRI 11-13-2024
- NLSP 01-21-2025
- Dividend Yield
- BFRI N/A
- NLSP N/A
- EPS Growth
- BFRI N/A
- NLSP N/A
- EPS
- BFRI N/A
- NLSP N/A
- Revenue
- BFRI $35,358,000.00
- NLSP N/A
- Revenue This Year
- BFRI $17.69
- NLSP N/A
- Revenue Next Year
- BFRI $19.71
- NLSP N/A
- P/E Ratio
- BFRI N/A
- NLSP N/A
- Revenue Growth
- BFRI 5.17
- NLSP N/A
- 52 Week Low
- BFRI $0.61
- NLSP $1.73
- 52 Week High
- BFRI $2.46
- NLSP $20.80
- Technical
- Relative Strength Index (RSI)
- BFRI 55.85
- NLSP 48.94
- Support Level
- BFRI $0.96
- NLSP $2.04
- Resistance Level
- BFRI $1.87
- NLSP $2.70
- Average True Range (ATR)
- BFRI 0.16
- NLSP 0.32
- MACD
- BFRI 0.00
- NLSP 0.10
- Stochastic Oscillator
- BFRI 17.58
- NLSP 46.15
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.